VivePeptides logo

Research Use Only

Peptides for Muscle Growth

A collection of growth-factor and secretagogue research peptides studied in the context of myogenesis and lean tissue accretion.

Peptides for Muscle Growth are research compounds studied for their roles in modulating growth hormone secretion and insulin-like growth factor receptor signaling in skeletal muscle and adipose tissue models. This category encompasses GHRH analogs, ghrelin receptor agonists, and long-acting IGF-1 receptor agonists, including IGF-1 LR3, Sermorelin, CJC 1295 No DAC combined with Ipamorelin, and Tesamorelin. All compounds are intended for laboratory research use only.

Reviewed by the VivePeptides Research DeskLast reviewed

Research Catalog

Compounds in this collection

IGF-1LR3 research peptide vial

IGF-1LR3

$109.00View
Sermorelin research peptide vial

Sermorelin

$79.00View
CJC 1295 No DAC + Ipamorelin Blend research peptide vial

CJC 1295 No DAC + Ipamorelin Blend

$90.00View
Tesamorelin research peptide vial

Tesamorelin

$69.00View

Research Overview

Muscle Growth Peptides: What This Research Category Covers

The muscle growth peptides research category encompasses compounds that modulate growth hormone axis signaling and direct growth factor receptor activation in skeletal muscle and adipose tissue models. This is an active area of preclinical investigation: the GH/IGF-1 axis governs protein synthesis, satellite cell recruitment, and nitrogen retention in mammalian tissue studies, making it a mechanistically rich target for study.

The compounds in this collection represent three mechanism classes: GHRH analogs (Sermorelin, CJC 1295 No DAC, Tesamorelin), ghrelin receptor agonists (Ipamorelin, supplied as a blend with CJC 1295 No DAC), and long-acting IGF-1 analogs (IGF-1 LR3). VivePeptides supplies each compound at research grade with lot-specific purity documentation to support reproducible experimental conditions.

Researchers working across in vitro and in vivo model systems will find representation of all three mechanism classes in this collection. All compounds are available for laboratory research use only and are not intended for human or veterinary application.

Three Distinct Receptor Pathway Classes

This collection spans GHRH analogs, ghrelin receptor agonists, and direct IGF-1 receptor agonists, allowing researchers to interrogate multiple nodes of the GH/IGF-1 axis within a single study framework. Each mechanism class represents a discrete point of intervention, supporting comparative and combinatorial study designs.

Upstream vs. Downstream Signaling Selection

Choosing between pituitary-targeting GHRH analogs and the peripheral receptor agonist IGF-1 LR3 is a foundational variable in GH axis study design. The CJC 1295 No DAC and Ipamorelin blend offers a dual-pathway option, engaging both GHRH and ghrelin receptor systems within a single preparation.

Purity Documentation for Reproducible Studies

Each compound in this collection is supplied with lot-specific purity verification to meet the documentation standards required for reproducible laboratory research. Researchers can review specification data prior to procurement to confirm compound suitability for their specific model system.

Compound Comparison

How these compounds compare

CompoundMechanism ClassResearch FocusDistinguishing Feature
IGF-1 LR3IGF-1 receptor agonistPeripheral receptor-level activationBypasses pituitary, extended half-life
SermorelinGHRH analogPituitary GH release stimulationShort N-terminal GHRH fragment
CJC 1295 No DAC + Ipamorelin BlendGHRH analog plus ghrelin receptor agonistDual-pathway GH secretionTwo-receptor stimulation, single preparation
TesamorelinGHRH analogGH secretion in adipose tissue modelsFull-length GHRH sequence retained

Mechanism & Research Context

Mechanism Classes and Research Context for GH Axis Peptides

The mechanism classes within this muscle growth peptides collection differ in where they intervene along the GH/IGF-1 signaling cascade. GHRH analogs, including Sermorelin, CJC 1295 No DAC, and Tesamorelin, act at the pituitary level to stimulate endogenous growth hormone release in model systems.

Ipamorelin, a selective ghrelin receptor agonist, provides a complementary GH secretagogue signal through a distinct receptor pathway, and preclinical literature has examined whether combining it with a GHRH analog produces additive secretion patterns. IGF-1 LR3, by contrast, is a modified IGF-1 analog that bypasses the pituitary and acts directly on IGF-1 receptors in peripheral tissues, including skeletal muscle.

Researchers select between these compounds based on whether the study design targets upstream pituitary stimulation, downstream receptor activation, or a combined approach. Compound half-life, binding affinity, and receptor selectivity differ across the group, making mechanism class a primary study design variable.

Research FAQ

Frequently asked questions

What are peptides for muscle growth in a research context?

Peptides for muscle growth are research compounds studied for their interactions with the GH/IGF-1 signaling axis in skeletal muscle and adipose tissue models. The category includes GHRH analogs that stimulate pituitary GH release, ghrelin receptor agonists that provide a complementary secretagogue signal, and IGF-1 receptor agonists that act directly on peripheral tissues. All compounds in this category are supplied for laboratory research use only and are not intended for human or veterinary application.

How does IGF-1 LR3 differ mechanistically from the GHRH analogs in this collection?

IGF-1 LR3 acts directly on peripheral IGF-1 receptors in tissue models rather than stimulating growth hormone release from the pituitary, which is the shared mechanism of the GHRH analogs Sermorelin, CJC 1295 No DAC, and Tesamorelin. This positions IGF-1 LR3 as the downstream intervention in the GH/IGF-1 cascade, while the GHRH analogs operate upstream at the pituitary. Researchers whose study designs target receptor-level signaling independent of pituitary function frequently select IGF-1 LR3 for that reason.

What is the mechanism of the CJC 1295 No DAC and Ipamorelin blend?

The CJC 1295 No DAC and Ipamorelin blend combines a GHRH analog with a selective ghrelin receptor agonist, simultaneously engaging two distinct receptor pathways that both contribute to growth hormone release. Preclinical literature has examined whether this dual-pathway stimulation produces additive GH secretion patterns compared to either compound administered alone. Researchers use this blend format when study designs call for multi-receptor interrogation within a single compound preparation.

How do researchers distinguish between Sermorelin and Tesamorelin for GH axis studies?

Sermorelin and Tesamorelin are both GHRH analogs that stimulate pituitary GH release but differ in peptide sequence length and pharmacokinetic profile, which are primary criteria in study design selection. Tesamorelin retains the full-length GHRH(1-44) sequence, while Sermorelin is a shorter N-terminal fragment, and preclinical literature has examined each across distinct model types. Researchers typically evaluate binding affinity characteristics, half-life, and the requirements of their specific tissue model before selecting between these two compounds.

What purity and documentation standards apply to these muscle growth research peptides?

Each muscle growth peptide supplied by VivePeptides comes with lot-specific purity verification and documentation designed to support reproducible laboratory research conditions. Consistent purity standards across research-grade compounds are critical for data integrity in replicate experiments and for valid comparisons between laboratory sites. Researchers should review available product documentation before procurement to confirm that compound specifications align with their study design requirements.

Are these peptides investigated in both in vitro and in vivo research models?

The muscle growth peptides in this collection, including IGF-1 LR3, Sermorelin, CJC 1295 No DAC combined with Ipamorelin, and Tesamorelin, have been investigated in both in vitro cell-based assays and in vivo preclinical animal models in the published research literature. Compound selection, reconstitution protocols, and concentration ranges should be determined by the specific model system in use and the applicable institutional research guidelines. All compounds are supplied for laboratory research use only and carry no indication for clinical, diagnostic, or therapeutic application.

Related Research Collections

Continue exploring

Growth Hormone PeptidesPeptides for BodybuildingPeptides for Weight LossGLP-1 Peptides

All products are sold strictly for laboratory and scientific research use only. Not for human or animal consumption, diagnostic, or therapeutic use. Nothing on this page constitutes medical advice or a health claim.